|
KR0166088B1
(ko)
|
1990-01-23 |
1999-01-15 |
. |
수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5840867A
(en)
|
1991-02-21 |
1998-11-24 |
Gilead Sciences, Inc. |
Aptamer analogs specific for biomolecules
|
|
GB9126677D0
(en)
|
1991-12-16 |
1992-02-12 |
Johnson Matthey Plc |
Improvements in chemical compounds
|
|
CA2171761C
(en)
|
1993-09-14 |
2011-11-15 |
Timothy John Williams |
Eotaxin: eosinophil chemotactic cytokine
|
|
JP3367581B2
(ja)
|
1993-10-14 |
2003-01-14 |
小野薬品工業株式会社 |
新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞
|
|
US6806061B1
(en)
|
1995-01-19 |
2004-10-19 |
Children's Medical Center Corporation |
G protein-coupled receptor gene and methods of use therefor
|
|
US6699843B2
(en)
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
AU1208397A
(en)
|
1995-12-28 |
1997-07-28 |
Takeda Chemical Industries Ltd. |
Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
|
|
DE69709647T2
(de)
|
1996-05-20 |
2002-11-07 |
Dupont Pharmaceuticals Research Laboratories, Inc. |
Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
|
|
EP1003743A4
(en)
|
1997-01-21 |
2001-04-11 |
Merck & Co Inc |
3,3-DISBSTITUED PIPERIDINE LIKE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
|
|
KR100447553B1
(ko)
|
1997-02-26 |
2004-09-08 |
화이자 인코포레이티드 |
헤테로아릴-헥사노산 아미드 유도체, 그의 제조 방법 및 ｍｉｐ-1 알파의 ｃｃｒ1 수용체로의 결합에 대한 선택적 저해제로서의 용도
|
|
US6207155B1
(en)
|
1997-05-07 |
2001-03-27 |
Schering Corporation |
Method of eosinophil depletion with antibody to CCR 3 receptor
|
|
GB9711643D0
(en)
|
1997-06-05 |
1997-07-30 |
Janssen Pharmaceutica Nv |
Glass thermoplastic systems
|
|
JP4312957B2
(ja)
|
1998-01-15 |
2009-08-12 |
キングス・カレツジ・ロンドン |
Ｃｃｒ５あるいはｃｘｃｒ４を開裂するリボザイム核酸
|
|
AU760208B2
(en)
|
1998-02-27 |
2003-05-08 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
G protein-coupled receptor antagonists
|
|
US6180348B1
(en)
|
1998-04-20 |
2001-01-30 |
Weihua Li |
Method of isolating target specific oligonucleotide ligands
|
|
CA2235420A1
(en)
|
1998-06-17 |
1999-12-17 |
Paolo Renzi |
Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
|
|
EP1050583A4
(en)
|
1998-11-24 |
2005-02-02 |
Hisamitsu Pharmaceutical Co |
INHIBITORS OF HIV INFECTIONS
|
|
US6723538B2
(en)
|
1999-03-11 |
2004-04-20 |
Micromet Ag |
Bispecific antibody and chemokine receptor constructs
|
|
BR0010655A
(pt)
|
1999-03-24 |
2002-02-13 |
Anormed Inc |
Compostos heterocìclicos para ligação ao receptor de quimiocina
|
|
CA2399080C
(en)
|
2000-02-03 |
2013-05-21 |
Millennium Pharmaceuticals, Inc. |
Humanized anti-ccr2 antibodies and methods of use therefor
|
|
BRPI0108923B8
(pt)
|
2000-03-03 |
2021-05-25 |
Cambridge Antibody Tech Limited |
elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
|
|
US6946546B2
(en)
|
2000-03-06 |
2005-09-20 |
Cambridge Antibody Technology Limited |
Human antibodies against eotaxin
|
|
GB0016138D0
(en)
|
2000-06-30 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
|
AU2002251913A1
(en)
|
2001-02-02 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
|
US20050124569A1
(en)
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
|
|
EP1461300B1
(en)
|
2001-11-30 |
2011-07-27 |
Biogen Idec MA Inc. |
Antibodies against monocyte chemotactic proteins
|
|
AR041786A1
(es)
|
2002-03-15 |
2005-06-01 |
Novartis Ag |
Derivados de azetidina como antagonistas del receptor ccr-3, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la elaboracion de un medicamento
|
|
GB0212357D0
(en)
|
2002-05-29 |
2002-07-10 |
Glaxo Group Ltd |
Novel compounds
|
|
PL375263A1
(en)
|
2002-07-02 |
2005-11-28 |
F.Hoffmann-La Roche Ag |
2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists
|
|
AU2003294290A1
(en)
|
2002-11-15 |
2004-06-15 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
|
|
AU2004215679A1
(en)
|
2003-02-27 |
2004-09-10 |
F. Hoffmann-La Roche Ag |
CCR-3 receptor antagonists
|
|
US20050069955A1
(en)
|
2003-06-30 |
2005-03-31 |
Daniel Plaksin |
Antibodies and uses thereof
|
|
AR046594A1
(es)
|
2003-10-16 |
2005-12-14 |
Applied Research Systems |
Usos terapeuticos de variantes de quemoquina
|
|
JP2007523159A
(ja)
|
2004-02-20 |
2007-08-16 |
ジェネシス リサーチ アンド デベロップメント コーポレイション リミテッド |
Ｒｎａ干渉分子の標的送達
|
|
AR049386A1
(es)
|
2004-05-26 |
2006-07-26 |
Janssen Pharmaceutica Nv |
Mercaptoimidazoles como antagonistas del receptor ccr2
|
|
US20060069123A1
(en)
|
2004-09-28 |
2006-03-30 |
Mingde Xia |
Substituted dipiperidine CCR2 antagonists
|
|
AU2006203826A1
(en)
|
2005-01-07 |
2006-07-13 |
Emory University |
CXCR4 antagonists for the treatment of HIV infection
|
|
US7622583B2
(en)
|
2005-01-14 |
2009-11-24 |
Chemocentryx, Inc. |
Heteroaryl sulfonamides and CCR2
|
|
PE20061444A1
(es)
|
2005-05-19 |
2007-01-15 |
Centocor Inc |
Anticuerpo anti-mcp-1, composiciones, metodos y usos
|
|
GB0517966D0
(en)
|
2005-09-02 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
|
HUP0500877A2
(en)
|
2005-09-22 |
2007-05-29 |
Sanofi Aventis |
Amide derivatives as ccr3 receptor ligands, process for producing them, pharmaceutical compositions containing them and their use and intermediates
|
|
WO2007147026A2
(en)
|
2006-06-15 |
2007-12-21 |
Centocor, Inc. |
Ccr2 antagonists for chronic organ transplantation rejection
|
|
WO2008049874A1
(en)
|
2006-10-27 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
Piperidyl-propane-thiol ccr3 modulators
|
|
CL2008001467A1
(es)
|
2007-05-30 |
2008-12-05 |
Lilly Co Eli |
Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
|
|
PL2175859T3
(pl)
|
2007-07-12 |
2012-09-28 |
Chemocentryx Inc |
Skondensowane heteroarylopirydylo- i fenylo-benzenosulfonamidy jako modulatory CCR2 do leczenia zapalenia
|
|
WO2009074807A2
(en)
*
|
2007-12-12 |
2009-06-18 |
Imperial Innovations Limited |
Methods
|
|
HUP0800478A2
(en)
|
2008-07-31 |
2010-03-01 |
Sanofi Aventis |
Substituted pyrrolidinyl-[1,3]thiazolo[4,5-b]pyridin derivatives as ccr3 receptor ligands
|
|
WO2010069979A1
(en)
|
2008-12-16 |
2010-06-24 |
Nycomed Gmbh |
Pyran derivatives as ccr3 modulators
|
|
HUE025547T2
(en)
|
2008-12-19 |
2016-02-29 |
Boehringer Ingelheim Int |
Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
|
|
US8278302B2
(en)
|
2009-04-08 |
2012-10-02 |
Boehringer Ingelheim International Gmbh |
Substituted piperidines as CCR3 antagonists
|
|
CN102459227B
(zh)
|
2009-04-17 |
2014-08-20 |
詹森药业有限公司 |
Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
|
|
US8471004B2
(en)
|
2009-10-07 |
2013-06-25 |
Hoffman-La Roche Inc. |
Bicyclic compounds
|
|
US8445674B2
(en)
|
2009-10-21 |
2013-05-21 |
Hoffmann-La Roche Inc |
Heterocyclyl compounds
|
|
JP5356323B2
(ja)
*
|
2010-07-01 |
2013-12-04 |
富士化学工業株式会社 |
新規な非晶質ボセンタン及びその製造方法
|
|
CN103298786B
(zh)
|
2010-10-11 |
2016-01-20 |
埃克希金医药品有限公司 |
芳基磺酰胺盐ccr3拮抗剂
|
|
US8921559B2
(en)
|
2010-12-01 |
2014-12-30 |
Janssen Pharmaceutica Nv |
4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2
|
|
EP2685824A4
(en)
|
2011-03-17 |
2014-09-10 |
Merck Sharp & Dohme |
INDUSTRIAL DERIVATIVES USED AS CCR2 ANTAGONISTS
|
|
US20140178367A1
(en)
|
2011-04-07 |
2014-06-26 |
The Brigham And Women's Hospital, Inc. |
Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2)
|
|
HK1197159A1
(en)
*
|
2011-05-25 |
2015-01-09 |
Intermune, Inc. |
Pirfenidone and anti-fibrotic therapy in selected patients
|
|
WO2013000922A1
(en)
|
2011-06-27 |
2013-01-03 |
Universite Pierre Et Marie Curie (Paris 6) |
Ccr2 antagonist peptides
|
|
WO2013052844A1
(en)
*
|
2011-10-07 |
2013-04-11 |
Pulmatrix, Inc. |
Methods for treating and diagnosing respiratory tract infections
|
|
AU2011379300A1
(en)
*
|
2011-10-18 |
2014-06-05 |
Biocon Limited |
Acid addition salts of Bosentan
|
|
US8822460B2
(en)
|
2012-04-06 |
2014-09-02 |
Janssen Pharmaceutica Nv |
Fused cyclopentyl antagonists of CCR2
|
|
US20160015786A1
(en)
*
|
2013-03-01 |
2016-01-21 |
Mater Medical Research Institute Limited |
Mobilizing agents and uses therefor
|
|
WO2014143807A2
(en)
*
|
2013-03-15 |
2014-09-18 |
Stromatt Scott |
Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
|